Navigation Links
Immucor Announces Fiscal Year 2009 Revenue and Earnings Guidance
Date:6/4/2008

NORCROSS, Ga., June 4 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced revenue and earnings guidance for the fiscal year ending May 31, 2009.

For fiscal year 2009:

-- The company expects revenues to range from $292 million to

$300 million.

-- Gross margin is expected to be in the range of 70% to 71%.

-- Net income is expected to be in the range of $80.0 million to

$83.0 million.

-- We expect to generate earnings per diluted share in the range of

$1.11 to $1.15.

We base our projections on our history of operations, the recurring nature of a significant portion of our revenues, including contractually committed purchases from large customers, and the predictability of our expenses through the fiscal year.

In making this projection, management has made the following assumptions:

-- With respect to revenues, the Company has extrapolated recent past

results and assumed the Company will generate additional revenues from

the implementation of our price strategy, the continuing sales of the

Galileo(R) and Echo(R) instruments in North America, Japan and Europe

and the reagent growth associated with these instrument placements.

-- With respect to the pending BioArray acquisition, the Company has

excluded the impact of the acquisition from these projections. As

previously announced the Company expects dilution of approximately

$0.20 to $0.23 in EPS in the first full year of operations following

closing, including approximately $0.05 per share of dilution resulting

from non-cash amortization expense.

-- With respect to stock based compensation expense, the Company expects

an increase of approximately $1.0 million.

Immucor, Inc. will host a confe
'/>"/>

SOURCE Immucor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Immucor CEOs Italian Trial Moves Toward Second Phase
2. Immucor To Acquire BioArray Solutions Ltd.
3. Immucor Responding to FTC Inquiry
4. Immucor Settles SEC Investigation
5. Martek Announces Second Quarter 2008 Financial Results
6. WWMR, Inc. Announces Launch of New Pain Clinic Monitor
7. China Kangtai Cactus Biotech Announces Improved Milk Production in Cows From Companys Cactus Cattle Feed
8. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
9. Exelixis Announces June 10 Webcast of Presentation at the Goldman Sachs 29th Annual Global Healthcare Conference
10. Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment
11. Cynosure Announces Schedule of Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... IDAHO (PRWEB) March 05, 2015 ... Ultralight Histology’s paraffin and stain additive. The improvement ... observe the binary features present in all daughter ... FFPE protocol, chromatin packaging was analyzed at 1000-1600x ... indicated that chromatin patterning in all daughter cells ...
(Date:3/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4ld5nw/mature_biotech ) ... Outlook 2015: New Therapy Ventures Pave the Way for ... All biotech companies - Gilead (GILD), Amgen (AMGN), Biogen ... given a positive return and hence increased the interest ... select therapy/niche indication where the high treatment cost justifies ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 ... acute and chronic orthopedic conditions such as meniscal ... tennis elbow, and joint pain due to degenerative ... administered during orthopedic surgeries to promote better post-surgical ... advances in nearly pain-free bone marrow harvesting with ...
(Date:3/4/2015)... March 4, 2015  Brooklyn residents now have a ... chronic pain and injuries. Nunzio Saulle , M.D., ... opening of his NJS Physical Medicine and Rehabilitation (PM&R) ... Thursday, March 5, 2015. Health Plus Management, LLC is ... located at 1178 Flatbush Avenue. This new PM&R practice ...
Breaking Biology Technology:Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 4Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 5NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2
... State University of Pennsylvania (USA) and the Universidad Autnoma ... biological structures, such as butterfly wings, on a nano ... optically active structures, such as optical diffusers for solar ... to change colours depending on the angle) or their ...
... Germany, October 9 Pieris AG, the,biopharmaceutical company ... protein therapeutics, today reported continued progress in development,of ... Under its manufacturing agreement ... biopharmaceuticals, Pieris has,successfully completed the first cGMP run ...
... Oct. 9 Soligenix, Inc. (Soligenix or the Company), ... today that Robert J. Rubin, MD, has been appointed ... had a distinguished career in the healthcare industry and ... president of the national health policy and management consulting ...
Cached Biology Technology:Nanometric butterfly wings created 2Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist 2Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist 3Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors 2Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors 3Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors 4
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ( ... - A Global Market Overview" report to their offering. ... is to ensure that an individual is who she/he is ... make use of a person,s unique physical characteristics, such as ...
(Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( ... launched its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz ... build of production capacity to meet customer demand. ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
Breaking Biology News(10 mins):Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... Depressed individuals with a tendency to ruminate on ... thoughts or memories, show different patterns of brain network ... new study in Biological Psychiatry . The ... tendency towards negative ruminations, but patterns of autobiographic memory ...
... in German . , Neutrophil granulocytes comprise ... the body, they are the first on the scene to ... risk. To this end, they release serine proteases enzymes ... at the Max Planck Institute of Neurobiology in Martinsried have ...
... a smoking gun proving that increased fertilizer use over the ... atmospheric nitrous oxide, which is a major greenhouse gas contributing ... the cause of the increased nitrous oxide was nitrogen-based fertilizer, ... nitrous oxide at a faster rate than normal. ...
Cached Biology News:Activity in brain networks related to features of depression 2New immune defense enzyme discovered 2New immune defense enzyme discovered 3Fertilizer use responsible for increase in nitrous oxide in atmosphere 2Fertilizer use responsible for increase in nitrous oxide in atmosphere 3Fertilizer use responsible for increase in nitrous oxide in atmosphere 4
... Signet offers the most comprehensive, ... requirements. We have incorporated unprecedented quality ... capabilities. This includes proven detection chemistries ... to the TechMate protocol. It also ...
Functionally tested for consistent G-banding of chromosomes....
... Cell Medium is optimized for serum-free growth ... In this protein-free medium, Sf9 cultures routinely ... cells/ml with viabilities above 95%. This medium ... color from X-gluc staining of pBACgus recombinants ...
... Insect Medium is formuatled for the ... Sf9 and Sf21 cells. Grace's Insect ... because it does not contain lactalbumin ... with transfection. Grace's Insect Medium, Supplemented ...
Biology Products: